Larvol Delta - Atsena-Therapeutics-Initiates-Part-B-of-Phase-III-Clinical-Trial-Evaluating-Gene-Therapy-ATSN201-to-Treat-Xlinked-Retinoschisis

ATSN-201 - Atsena Therap

https://www.globenewswire.com/news-release/2025/01/08/3006142/0/en/Atsena-Therapeutics-Initiates-Part-B-of-Phase-I-II-Clinical-Trial-Evaluating-Gene-Therapy-ATSN-201-to-Treat-X-linked-Retinoschisis.html

Jan 8, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next